ANIP News & Events

Reports Q4 revenue $247.1M, consensus $231.03M. "2025 was a year of significant growth for our Rare Disease and Generics businesses, which drove expansion to both our top- and bottom-line," said Nikhil Lalwani, President and CEO of ANI. "We are building on this momentum as we continue to focus on our key 2026 priority of accelerating our transformation into a leading Rare Disease company, supported by strong execution in Generics and disciplined capital deployment." Lalwani continued, "We see a significant multi-year growth opportunity for Cortrophin Gel as we expand in underpenetrated specialty indications and launch a dedicated organization for acute gouty arthritis flares. With a proven track record, we expect to deliver more than $1 billion in revenue in 2026, with Rare Disease representing approximately 60% of total revenue, while continuing to fulfill our purpose of Serving Patients, Improving Lives."

Sees FY26 revenue $1.055B-$1.115B, consensus $1.04B. Sees FY26 adjusted EBITDA $275M-$290M.

Provides full year 2026 financial guidance, which includes: Total net revenues of $1.055B-$1.115B; Cortrophin Gel net revenues of $540M-$575M; Adjusted non-GAAP EBITDA of $275M-$290M; Rare Disease business to represent approximately 60% of total net revenues. Announces ~90-person expansion of Rare Disease organization to capture unique opportunity for Cortrophin Gel in acute gouty arthritis flares; expected to deploy in mid-2026.